← Eichor
Study identifier: NCT04997096 Synced from ClinicalTrials.gov · July 29, 2026
● Recruiting

Exercise as a Preventive Agent to Combat Immobility in Patients With Ovarian or Endometrial Cancers Receiving Chemotherapy

Condition: Ovarian Cancer · Ovarian Carcinoma · Ovarian Cancer Stage IV  ·  Sponsor: Dana-Farber Cancer Institute

PhaseNA
Planned participants30
Who can joinFemale, 18 Years to no upper limit
Healthy volunteersNo

About this study

The purpose of this research is to determine whether a 16-week virtually supervised aerobic and resistance exercise program is feasible in patients receiving first-line chemotherapy after surgery for ovarian or endometrial cancer and if it will improve lower extremity function (function of the legs), lessen chemotherapy-induced peripheral neuropathy (CIPN; numbness or tingling in the hands or feet), and if there is any effect on inflammatory blood markers (the level of a certain marker in the blood that is associated with inflammation; redness and swelling).

This description comes directly from the study's public registry record.

Talk to the study team

Christina Dieli-Conwright, PhD  ·  (617) 582-8321  ·  ChristinaM_Dieli-Conwright@dfci.harvard.edu

Always discuss trial participation with your own doctor first.

Locations (1)

Dana Farber Cancer InstituteBoston, Massachusetts, United StatesRecruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT04997096